Gene Therapy · global
RNA Delivery, Lasting Gene Addition: Addition Reports Fabry Disease Mouse Study
After a single dose, enzyme activity in Fabry disease model mice persisted through week 16, while disease-related metabolites fell by about 80% in multiple organs. This nonviral gene addition technology also produced enzyme expression in nonhuman primates, but whether it can protect patients’ organs remains to be clinically validated.
For Fabry disease treatment, replacing the missing enzyme is only the starting point; sustaining its supply and reducing metabolite buildup in the heart and kidneys are the long-term challenges. Addition Therapeutics announced preclinical research on October 27, reporting that its PRINT platform enabled disease model mice to continue producing the enzyme after a single dose and reduced disease-related markers in multiple organs, providing new animal evidence for nonviral gene therapy.
Fabry disease results from variants in the GLA gene that cause insufficient activity of α-galactosidase A (α-Gal A), leading to the accumulation of Gb3 and related metabolites. According to the company’s announcement, after researchers administered a PRINT formulation encapsulated in lipid nanoparticles to mice lacking the GLA gene, plasma enzyme activity remained above normal physiological levels through week 16, when the study ended; lyso-Gb3 levels in plasma, liver, kidneys, and heart fell by about 80%. However, a reduction in metabolites does not mean that improved organ function has been demonstrated.
PRINT’s description as “all-RNA” refers to its delivery format; its goal remains to add a gene capable of sustained expression. The research title listed in the official program of the European Society of Gene and Cell Therapy (ESGCT) describes RNA-mediated transgene insertion using an R2 retrotransposase to enable sustained production of therapeutic proteins in the liver. The program confirms that Gregory Cost’s OR045 presentation was scheduled for the genome editing session on the morning of October 29; the company also listed the Fabry disease study as poster P0746, presented by Francine Gregoire. The program allows verification of presentation arrangements but does not constitute independent validation of the efficacy data.
Moving from mice to larger animals, the company said that similar α-Gal A levels were also achieved in nonhuman primates, but the announcement did not provide detailed doses, sample sizes, or follow-up duration. Another round of platform optimization increased enzyme activity by about tenfold in mice and is currently being tested in nonhuman primates; this increase cannot yet be regarded as having been reproduced in primates, nor can it be directly translated into the dose required in humans.
Sustained expression also raises a question of control: if protein production is too high, can it be lowered after dosing? In a separate preclinical study involving an engineered incretin, the company incorporated an “off switch” activated by a small-molecule drug, reducing levels of the protein produced by about 90%. This provides proof of concept for regulating output, but it is not evidence that the Fabry disease approach already has the same control capability, nor does it mean that the inserted gene can be removed.
### Background
Development of long-acting treatments for Fabry disease aims to reduce the burden of repeated enzyme replacement. Compared with gene therapies delivered using adeno-associated virus (AAV), Addition has chosen lipid nanoparticles and RNA, and lists repeat dosing as a potential advantage. However, whether additional doses can be administered safely, whether immune responses occur, and the long-term effects of gene insertion all require direct evidence and cannot be inferred solely from the nonviral design.
The publicly available evidence currently consists mainly of the company’s announcement and conference presentation information, which are not yet sufficient for a full assessment of statistical reliability, dose response, and long-term safety. These results support further research, but they have yet to answer the questions that matter most to patients: how long the enzyme supply can be maintained, and whether lower metabolite levels can truly slow kidney and heart damage.